Yamanouchi Pharmaceutical Company Ltd.

Hiroitsu Kawata

Masayoshi Aruga

Takashi Sonobe

Tadayoshi Ohmura

Yutaka Konno

Satoru Yoneya

Mitsuo Mitomi

Chiharu Sone

Yukio Kubota

Masuo Murakami

Hiroshi Sugiura

Shunji Hasumi

Jun Sekino

Hidemi Shimizu

Kiyoshi Okazaki

Shigemi Kawahara

Toshimitsu Konno

Tomoh Itoh

Ken Iwai

Hiroshi Maeda

Muneo Fukui

Akira Okada

Katsuhiko Yano

Hiroyoshi Shiozawa

Saburo Higuchi

Yoshiaki Soeishi

Yoichi Setoguchi

Tadamasa Kawase

Munetaka Hattori

Chiharu Yamada

Mikio Matsumura

Seiki Tashiro

Kenichi Muraoka

Hisamoto Komatsu

Makoto Uchida

A patch having good transdermal property which utilizes a suppository base e.g. triglyceride of a vegetable saturated fatty acid having 12 to 18 carbon atoms together with a penetration enhancer.

Patch

An oily composition of aclarubicin or aclarubicin hydrochloride comprising aclarubicin or aclarubicin hydrochloride; at least one fatty acid selected from saturated medium chain fatty acids, unsaturated medium chain fatty acids and unsaturated long chain fatty acids; and at least one fats and oils selected from iodized oils and vegetable oils.

Oily composition of aclarubicin or hydrochloride thereof

Long acting formulations of amosulalol hydrochloride are provided, wherein the frequency of administering the hypotensive agent is minimized and wherein such formulations are prepared by compounding amosulalol hydrochloride with an enterosoluble material and optionally the inclusion of an organic acid.

Amosulalol hydrochloride long acting formulations

A spherical pellet like composition of nicardipine composed of small granular nuclei such as sugar particles coated with amorphous nicardipine or a salt thereof, a pH-dependent additive and a surface active agent. The spherical pellet like composition of nicardipine may have a further coating of a medicament permeating material as an outermost coating. The spherical pellet like composition may be mixed with the spherical pellet like composition coated with the medicament permeating material.

Composition for long acting nicardipine preparation and process of

Amosulalol hydrochloride long acting formulation

A granular composition of difficultly digestible polysaccharides (dietary fiber) is composed of a combination of one or more difficultly digestible polysaccharides selected from polysaccharides derived from roots of the plant such as glucomannan, polysaccharides derived from fruits of plants such as pectin, polysaccharides derived from seaweeds such as galactomannan, carragheenin, alginic acid, etc., various kinds of celluloses, and various kinds of brans and one or more difficultly digestible polysaccharides selected from alginates, alginic acid esters, agar, carboxymethyl cellulose salts, and pulullan. The granular composition of this invention is useful as a dietary food or dietary food additive.

Granular composition of difficult digestible polysaccharides

Sustained release pharmaceutical compositions of a solid medical material which contains an amorphous solid medical material, polyethylene oxide, and at least one basic substance selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl pyrrolidone, carboxyvinyl polymer, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, methyl meta-acrylate meta-acrylic acid copolymer, polyvinylacetal diethylaminoacetate, dimethylaminoethyl meta-acrylate meta-acrylic acid copolymer, 2-methyl-5-vinylpyridinemethyl acrylate meta-acrylic acid copolymer, citric acid, urea, succinic acid and amino acid, and may further contain one basic substance selected from the group consisting of a surface active agent, polyethylene glycol, propylene glycol, glycerin, a glycerin fatty acid ester and a vegetable oil (first embodiment); and in the case where the solid medical material in nicardipine, the composition may consist only of the amorphous nicardipine or a salt thereof without the above compound (second embodiment).

Sustained release pharmaceutical composition of solid medical material

A formulation is provided for the transdermal administration of nicardipine hydrochloride. The formulation is comprised of nicardipine hydrochloride dissolved or suspended in a mixed liquid composed of an urea and at least one compound selected from the group consisting of propylene glycol, a monohydric alcohol having 2 to 4 carbon atoms, lactic acid, thioglycol, a middle chain fatty acid glyceride and a sorbitan middle chain fatty acid ester compounded with a transdermal formulation base.

Transdermal formulation of nicardipine hydrochloride

An oily composition of an antitumor drug comprising at least one sparingly oil soluble or water-soluble antitumor drug, at least one fat or oil, and at least one solubilizing adjuvant in an oily vehicle selected from the group consisting of crown ether, lecithin, polyethylene glycol, propylene glycol, vitamin E, polyoxyethylene alkylether, and sucrose esters of fatty acids.

Oily compositions of antitumor drugs

A novel nifedipine-containing solid pharmaceutical preparation composition comprising a mixture of nifedipine and at least one 1st(a) substance selected from polyvinyl pyrrolidone, methyl cellulose, hydroxypropyl cellulose and hydroxypropylmethyl cellulose; a mixture of nifedipine, at least one 1st(b) substance selected from polyvinyl pyrrolidone, urea, citric acid mannitol, succinic acid, methyl cellulose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose and amino acid, and at least one 2nd substance selected from a surface active agent, polyethylene glycol, propylene glycol, glycerol, a glycerol fatty acid ester and a vegetable oil; or a mixture of nifedipine, the 1st(b) substance, the 2nd substance and calcium lactate. The composition of this invention can increase the bioavailability of nifedipine and makes it possible to provide a nifedipine-containing pharmaceutical preparation which has small bulk and can be easily administered.

Nifedipine-containing solid preparation composition

Sustained release pharmaceutical compositions of a solid medical material which contains an amorphous solid medical material, polyethylene oxide, and at least one basic substance selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl pyrrolidone, carboxyvinyl polymer, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, methyl meta-acrylate meta-acrylic acid copolymer, polyvinylacetal diethylaminoacetate, dimethylaminoethyl meta-acrylate meta-acrylic acid copolymer, 2-methyl-5-vinylpyridinemethyl acrylate meta-acrylic acid copolymer, citric acid, urea, succinic acid and amino acid, and may further contain one basic substance selected from the group consisting of a surface active agent, polyethylene glycol, propylene glycol, glycerin, a glycerin fatty acid ester and a vegetable oil (first embodiment); and in the case where the solid medical material is nicardipine, the composition may consist only of the amorphous nicardipine or a salt thereof without the above compound (second embodiment).

A solid microdose drug preparation containing a microdose drug such as formoterol fumarate or .beta.-methyldigoxin coated with wax. In the drug preparation, the stability and the content uniformity of the microdose drug have been improved.

Solid drug preparations

Sustained release pharmaceutical composition of a solid medical material which contains an amorphous solid medical material, polyethylene oxide, and at least one basic substance selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl pyrrolidone, carboxyvinyl polymer, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, methyl meta-acrylate meta-acrylic acid copolymer, polyvinylacetal diethylaminoacetate, dimethylaminoethyl meta-acrylate meta-acrylic acid copolymer, 2-methyl-5-vinylpyridinemethyl acrylate meta-acrylic acid copolymer, citric acid, urea, succinic acid and amino acid, and may further contain one basic substance selected from the group consisting of a surface active agent, polyethylene glycol, propylene glycol, glycerin, a glycerin fatty acid ester and a vegetable oil (first embodiment): and in the case where the solid medical material is nicardipine, the composition may consist only of the amorphous nicardipine or a salt thereof without the above compound (second embodiment).

A novel coating agent for solid medicaments containing a hydrogel-like substance of a water-insoluble hydroxypropyl cellulose having 5-16% by weight of a hydroxypropoxy group or the dry powder of a hydrogel-like substance. By coating solid medicaments with the coating agent, solid medicaments having high impact resistance and showing very less aging can be provided advantageously in industry.

Growing community of inventors

Saitama, Japan

Hiroitsu Kawata